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Carboxylesterases (CEs) are nonspecific hydrolytic enzymes and
responsible for the metabolism of xenobiotics and endobiotics that contain ester
bonds. There are two human CE isoforms found in liver, CES1 and CES2. In this
study it is shown that the mere abundance of CES1 protein expression in human
liver does not predict its biochemical activity. The human interindividual variation
in CES1 activities may attribute to several mechanisms. One possibility is the
presence of endogenous inhibitors in liver, arachidonic acid (AA) and 27hydroxycholesterol (27-HC). CES1 is also expressed in human
monocytes/macrophages and is proposed to catalyze the rate-limiting step of
cholesterol ester mobilization in macrophages. It is of interest to determine
whether CES1 can degrade the lipid mediators, 2-arachidonoylglycerol (2-AG),
prostaglandin E2-1-glyceryl ester (PGE2-G), and prostaglandin F2α-1-glyceryl

ester (PGF2α-G), in monocytes/macrophages and to determine if this metabolism
is inhibited by organophosphate pesticide exposure.
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CHAPTER I
INTRODUCTION

Carboxylesterases (CEs, EC 3.1.1.1) are nonspecific hydrolytic enzymes
found in organisms ranging from bacteria to humans. CEs are responsible for the
metabolism of xenobiotics and endobiotics that contain ester bonds (Cashman et
al., 1996). There are two CE isoforms found in human liver, CES1 and CES2.
CES1 is also expressed in human monocytes/macrophages, but CES2 is not. On
the other hand, CES2 is found in human intestine but CES1 is not. The CEs play
an important role in detoxifying oxons (bioactive metabolites of organophosphate
pesticides) by forming covalent adducts with these compounds, in addition to
hydrolyzing a number of ester-containing substrates including narcotic drugs,
therapeutic drugs, and environmental toxicants. Some organophosphate
pesticides, such as chlorpyrifos, diazinon, and parathion, do not produce their
main toxicity in their original form. An animal's liver can replace a phosphorussulfur bond with a phosphorus-oxygen bond, turning these chemicals into oxons.
Oxons can inhibit an enzyme (acetylcholinesterases) that breaks down
acetylcholine, which is an important neurotransmitter, and this is the primary
mechanism of their acute toxicity. Because of their abundance in livers, CEs
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are an important detoxification enzyme for the above organophosphates (Clement and Erhardt, 1990). The most important biological function of CEs may be the
hydrolysis and subsequent detoxification of xenobiotics, including pesticides and
drugs. However, physiological substrates of CEs are sure to exist but need to be
better characterized. For example, CES1 may have an important role in cholesterol mobilization in macrophages, and may catalyze the rate-limiting step of reverse cholesterol transport (Zhao et al., 2007).
The overall hypothesis of this thesis is that endobiotic and xenobiotic
inhibitors of carboxylesterases can modulate its function in vivo, which may
potentially explain human variation in carboxylesterase hepatic activity and
perturb the physiological function of these enzymes. The first aim of my thesis
was to investigate the CE activities in human livers and their interindividual
variations. The data obtained showed that 25 individual (healthy) human livers
exhibited marked differences in CE activities when using model substrates (pnitrophenyl valerate), pyrethroid insecticides (bioresmethrin), and activity-based
proteomic probes (biotin-tagged fluorophosphonate, FP-biotin). However, the
difference in CE activities in these individuals was not related to the protein level
of CES1, which is by far the most abundant CE isoform in human liver (60-fold
greater than CES2; Godin et al., 2007). The levels of CES1 protein in each
individual human liver sample are remarkably similar, while CES1 biochemical
activities are very different. To account for this, many different hypotheses have
been proposed: (1) endogenous inhibitors, such as small molecules, may inhibit
2

CES1; (2) exogenous inhibitors, such as organophosphate pesticide metabolites,
may inhibit CES1; (3) variations in amino acid sequence (polymorphisms) and/or
post-translational modifications (PTMs) in CES1 proteins may alter hydrolytic
activities. We have been interested to identify potential endogenous inhibitors of
CE activity in human liver. Two lipid compounds, arachidonic acid and 27hydroxycholesterol (see Scheme 1 below), were recently identified by us to be
potent endogenous inhibitors of CES1 activity, but not CES2 activity, when using
recombinant proteins, cultured cells, and human liver homogenates (Crow et al.,
2009). Arachidonic acid is a polyunsaturated fatty acid that is present in both
esterified and non-esterified forms in the phospholipid membranes of the body's
cells. 27-Hydroxycholesterol, on the other hand, is an oxysterol that acts as a
ligand for liver X receptors, which are important regulators of lipid homeostasis.
Thus, we hypothesized that the quantities of the endogenous CES1 inhibitors,
arachidonic acid and 27-hydroxycholesterol, in individual human livers were inversely correlated with CES1 biochemical activity.
Lipids have structural, energetic, and cell signaling functions. Endocannabinoids and prostaglandins are important classes of lipid mediators. They play
essential roles in immune regulation, self-defense, and the maintenance of homeostasis in living systems (Shimizu, 2008). Several lipid mediators contain
ester bonds, e.g. the endocannabinoid, 2-arachidonoyl glycerol (2-AG), and the
prostaglandin glycerol esters (PG-Gs; PGE2-G and PGF2α-G) (see Scheme 2). 2AG has been shown to be a selective cyclooxygenase-2 (COX-2) substrate.
3

Products of COX-2 action on this lipid have been identified as prostaglandin
glycerol esters (PG-Gs), which have their own diverse and potent biological activities (Kozak et al., 2001). Endocannabinoids and PG-Gs have been implicated
in development and progression of diabetes and atherosclerosis (Sugamura et
al., 2009). Identification of the enzymes that degrade lipid mediators and modulate their physiologic actions is important because of the potential to inhibit these
enzymes with selective inhibitors for the treatment of human disease. Therefore,
the second aim of my thesis investigated whether CEs can degrade the lipid mediators, 2-AG and PG-Gs, in immune cells and to determine if this ability can be
inhibited by OP pesticide exposure. The degradation of 2-AG and PG-Gs by recombinant human CEs and cultured cells (human THP1 monocytes / macrophages) that express CES1 was investigated. In addition, inhibition of this metabolism by a selective CES1 inhibitor and by bioactive metabolites of two commonly used OP insecticides was examined.

4

Arachidonic acid (AA)

27-Hydroxycholesterol (27-HC)

Scheme 1. Endogenous carboxylesterase 1 inhibitors

O

OH

O
OH

2-Arachidonoyl glycerol
(2-AG)

Prostaglandin E2-2-glyceryl ester
(PGE2-G)

Prostaglandin F2α-2-glyceryl ester
(PGF2α-G)

Scheme 2. Lipid mediators used as carboxylesterase substrates in this study
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CHAPTER II
LITERATURE REVIEW

Carboxylesterases: A promiscuous hydrolytic enzyme
CEs are enzymes that catalyze the hydrolysis of carboxylic esters to their
corresponding alcohols and carboxylic acids (Ileperuma et al., 2007), and the
conversion of largely lipophilic ester substrates to more water-soluble products,
facilitating their elimination (Brzezinski et al., 1997). CEs also efficiently catalyze
the hydrolysis of a variety of narcotic and therapeutic compounds, such as cocaine, heroin, CPT-11, temocapril, and benzoic acid derivatives (Taketani et al.,
2007). The highest amounts of CE protein are found in the liver (Satoh et al.,
2006). CEs are also predominantly involved in hydrolase activity in the small intestine of various mammals. It has been shown using native polyacrylamide gel
electrophoresis that CEs are the most abundant hydrolytic enzyme in the liver
and small intestine of humans, monkeys, dogs, rabbits and rats (David et al.,
1998). Besides animals, carboxylesterases are also widely distributed in plants
and microorganisms and catalyze the hydrolytic reactions of various short chain
fatty acid esters (Murase et al., 1991).

6

Most CE enzymes belong to the superfamily of hydrolases with the α/β
protein fold, which cleave carboxylesters (RCOOR’) by a mechanism that uses a
nucleophilic serine present within a Ser-His-Glu catalytic triad (Redinbo and Potter, 2005). In general, carboxylesterases exist as 60 kDa monomers, but a few
CEs exist as approximately 180 kDa because they associate to form homotrimers. Liver CEs are N-linked glycoproteins of the high-mannose type. Glycosylation of CEs occurs in the endoplasmic reticulum lumen and stabilizes the active
conformation of the protein. The mature CEs are localized to the luminal side of
the endoplasmic reticulum. They exist as multiple forms in terms of their isoelectric points and substrate specificities (David et al., 1998). The broad substrate
specificities of CEs allow the enzyme to metabolize a wide variety of estercontaining compounds (Brzezinski et al., 1997).
Based on the homology of the amino acid sequence, CEs can be classified into four major groups. The majority of CEs have been identified as members
of the CES1 or CES2 family (Hosokawa et al., 2008). In humans and rats, the
small intestine only contains enzymes from the CES2 family, while in rabbits and
monkeys enzymes from both the CES1 and CES2 families are present (Taketani
et al., 2007). CES1 and CES2 family enzymes share ~40–50% amino acid sequence; however, they show very different substrate specificities (Satoh et al.,
2002; Imai et al., 2006). The human CES1 catalyzes the hydrolysis of ester substrates that contain relatively “large” acyl groups compared with the alcohol group;
for example, temocapril, methylphenidate, and flurbiprofen. In contrast, the hu7

man CES2 isoform typically hydrolyze substrates with a “small” acyl group; for
example, CPT-11 and betamethasone valerate. Because the major CEs in human liver and small intestine are, respectively, CES1 and CES2, these organs
have remarkably different ester substrate specificities. Temocapril, methylphenidate, and flurbiprofen derivatives can be hydrolyzed in human liver, but not in
human small intestine. In contrast, CPT-11 and betamethasone valerate can be
efficiently hydrolyzed in human small intestine (Taketani et al., 2007).
The most important biological function of CEs may be the hydrolysis and
subsequent detoxification of xenobiotics, including pesticides and drugs. Many
pesticides contain organophosphate compounds that bind covalently to the active
site of the CE enzymes and inactivate their function (Miller et al., 1999). Because
of their abundance in livers, carboxylesterases are an important detoxification
route for organophosphates (Clement and Erhardt, 1990).

Arachidonic acid and 27-hydroxycholesterol
Arachidonic acid (AA) is pressed abundently in eukaryotic cells and can
be metabolized by cyclooxygenases, lipoxygenases, and cytochrome P450s to
produce prostaglandins (PGs), hydroperoxyeicosatetraenoic acid (HPETE), and
epoxyeicosatetrenoic acids (EETs), respectively. We have also found that
arachidonic acid is a relatively potent inhibitor of CES1 enzyme activity (Crow et
al., 2009). The concentration of esterified arachidonate in resting or unactivated
human cells (~30 μg arachidonate/109 platelets) corresponds to a molar concen8

tration of ~5 mM. Release of 1% of this reserve will give a free arachidonate concentration of 50 μM in the cell. Inflamed tissues often have free arachidonic acid
concentrations much higher than 50 μM (Brash, 2001).
27-Hydroxycholesterol (27-HC) is an oxysterol that is the enzymatic product of CYP27A-catalyzed oxidation of cholesterol. Its concentration relative to
cholesterol in normal human aorta is about 1.4 mg 27-HC/g cholesterol, which is
at least 10-fold greater than what is detected in plasma (Duane and Javitt, 1999).
The continual removal of 27-HC, and its metabolites, from vascular tissues into
plasma may represent an important component of “reverse cholesterol transport”,
contributing to overall cholesterol homeostasis (Duane and Javitt, 1999). 27-HC
is the most abundant hydroxycholesterol in human circulation (Fu et al., 2001). It
circulates in humans at a concentration between 75–730 nM, with ~90% existing
in an esterified form (DuSell and McDonnell, 2008).

Endocannabinoids
The endocannabinoid system refers to a group of lipids and their
receptors that are involved in a variety of physiological processes including
appetite regulation, pain-sensation, lipogenesis, inflammation, mood, and
memory. It is named for the endogenous lipids that bind cannabinoid receptors
(the same receptors that mediate the psychoactive effects of cannabis). Broadly
speaking, the endocannabinoid system refers to: the cannabinoid receptors CB1
and CB2, which are G-protein coupled receptors located in the central nervous
9

system and periphery; the endogenous arachidonate-based lipids, anandamide
(N-arachidonoyl ethanolamine or AEA) and 2-arachidonoylglycerol (2-AG),
collectively termed the "endocannabinoids", which are ligands for the
cannabinoid receptors; and the enzymes that biosynthesize and degrade AEA
and 2-AG. Unlike neurotransmitters, endogenous cannabinoids are not stored in
vesicles after synthesis, but are synthesized on demand. Structures of 2-AG and
AEA, and their hydrolysis by specific enzymes, are shown below (Scheme 3).
Cyclooxygenase-2 (COX-2) action on arachidonic acid (AA) and the endocannabinoid 2-arachidonylglycerol (2-AG) generates prostaglandins and prostaglandin glyceryl esters (PG-G), respectively. The diversity of PG-Gs that can be
formed enzymatically following COX-2 oxygenation of endocannabinoids was
previously examined in cellular and subcellular systems (Kozak et al. 2002).
Some metabolic reactions that describe their formation and hydrolysis are shown
below (Scheme 4).

Monoacylglycerol lipase (MAGL)
Monoacylglycerol lipase is a 33-kDa member of the serine hydrolase
superfamily. MAGL is a key enzyme in the hydrolysis of the endocannabinoid 2arachidonoylglycerol in the central nervous system (Dinh et al., 2002). It converts
2-AG to the free arachidonic acid and glycerol. The contribution of MAGL to total
brain 2-AG hydrolysis activity has been estimated to be ~85% (Blankman et al.,
2007). The compound N-arachidonoyl maleimide (NAM) can inhibit MAGL
10

(Burston et al., 2008). JZL184, which can elevate brain 2-AG levels in vivo, is
reported to be an even more selective and potent inhibitor of MAGL than NAM
(Long et al., 2009). JZL184 has >300-fold selectivity for MAGL over other brain
serine hydrolases.

O

OH

OH

O

HO
OH

+

MAGL

OH

2-Arachidonoyl glycerol
(2-AG)

O
OH

FAAH
O

arachidonic acid (AA)

OH

+

NH

OH
H2N

Anandamide
(AEA)

Scheme 3. Structures of 2-AG and AEA, and their hydrolytic metabolism by
monoacylglycerol lipase (MAGL), or fatty acid amide hydrolase
(FAAH).

11

O
OH
O
O
OH

HO

O

2O 2
COX-2

OH

O

OH
Prostaglandin E 2 (PGE2)

PG
synthases

O

OH
OH

OH
Prostaglandin H 2 (PGH 2)

Arachidonic acid

O
HO
OH
Prostaglandin F 2α (PGF 2α)

OH

O

O

O

O

OH
OH CEs

O
HO
OH

O

O
HO

OH
Prostaglandin E2 glyceryl ester (PGE2-G)
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+
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O
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O
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OH

Prostaglandin F2α glyceryl ester (PGF2α-G)

Prostaglandin F2α (PGF2α)

Scheme 4. Metabolic reactions that describe the conversion of arachidonic acid
to PGE2 and PGF2α (top scheme) and the conversion of 2-AG to PGGs (bottom scheme) by cyclooxygenase-2.
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CHAPTER III
MATERIALS AND METHODS

Reagents, chemicals and materials
Human THP-1 monocytes/macrophages and RPMI-1640 medium were
purchased from the American Type Culture Collection (ATCC) (Manassas, VA).
Fetal bovine serum (FBS) was purchased from Invitrogen (Carlsbad, CA). Trypan
Blue solution (0.4%), acetonitrile, phorbol 12-myristate 13-acetate (PMA), avidinHRP and all components of the buffers were purchased from Sigma (St. Louis,
MO). Paraoxon (PO) and chlorpyrifos oxon (CPO) were synthesized and provided as gifts by Dr. Howard Chambers (Mississippi State University). The CES1
specific inhibitor, S-3030, was a gift from Dr. Phil Potter (St. Jude Children’s
Hospital, Memphis, TN). Bioresmethrin was obtained from Chem Service (West
Chester, PA). N-arachidonoyl maleimide (NAM), arachidonic acid, 27hydroxycholesterol, prostaglandin E2-1-glyceryl ester, prostaglandin F2α-1glyceryl ester, 8-iso-prostaglandin F2α-d4, 2-arachidonoylglycerol, arachidonic
acid-d8, fatty acid amide hydrolase (FAAH), and monoacylglycerol lipase (MAGL)
were purchased from Cayman Chemical (Ann Arbor, MI). Brij 78 was purchased
from Acros Organics (New Jersey). Protein A-agarose be
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ads were purchased from Invitrogen (Carlsbad, CA). Rabbit pre-immune IgG was
purchased from Biomeda Corp (Foster City, CA). FP-biotin was from Toronto
Research Chemicals, North York, Ontario, Canada. The enhanced chemiluminescent substrate was from Pierce. Recombinant human CES1 and CES2 proteins were prepared by the method described by Morton and Potter (2000) in Dr.
Potter’s laboratory.

Cell culture conditions
THP-1 monocytes/macrophages were grown in suspension in RPMI-1640
medium supplemented with 10% FBS, 0.05 mM β-mercaptoethanol, and 50 μg
gentamicin/ml (growth medium) in a humidified incubator at 37° C, 95 % air and 5
% CO2. The cells were cultured at a density between 0.2 × 106 and 1 × 106
cells/ml, as recommended by ATCC.

Preparation of human liver S9 fractions
Twenty-five healthy human livers were obtained from the University of
Minnesota Liver and Tissue Procurement Service. These livers, from both males
and females, were procured from resected portions of livers intended for liver
transplants. Liver S9 fractions were prepared as described previously (Ross and
Pegram, 2004). S9 includes both the cytosolic and microsomal fractions of tissue
homogenates.
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Western blot analysis of CES1 in human livers (S9 fractions)
Preliminary experiments determined that 0.2 μg S9 protein was an amount
that would produce bands that did not saturate the film. Prior to electrophoresis
of human liver S9 fractions, each sample was spiked with an internal protein
standard (His-tagged β-actin, 1 μg). For quantitative analysis of CES1 and Histagged β-actin, PVDF membranes were probed with rabbit anti-CES1 (1:4000)
and mouse anti-His (1:5000) antibodies for 1h at room temperature. After washing, membranes were then incubated with goat anti-rabbit HRP and goat antimouse HRP secondary antibodies (1:20,000). Chemiluminescent signal were
captured on X-OMAT film. Quantitative analysis was done using 1D-Multi software from Alpha Innotech (San Leandro, CA) or Image J (NIH).

Interindividual variation in human hepatic CES1 activity: Bioresmethrin
hydrolysis reactions
We used the CES1-selective substrate bioresmethrin (a pyrethroid insecticide), to assay the biochemical activity of the human liver S9 samples. Briefly,
bioresmethrin substrate (50 µM) was pre-incubated in 50 mM Tris-HCl buffer (pH
7.4) for 5 min at 37 °C. After pre-incubation, human liver “S9” samples were
added to start reactions (total reaction volume, 250 μL) so that the final protein
concentration in the reactions was 0.5 mg/mL. After 15 min incubation (37 °C),
an equal volume of ice-cold acetonitrile containing the internal standard 3-(4methoxy)-phenoxybenzaldehyde (10 µM) was added in each tube to terminate
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the reaction. The tubes were centrifuged 5 min at 16,000 × g, 4 °C. Supernatants
were analyzed by HPLC-UV to assay bioresmethrin hydrolysis products, as described in Ross et al. (2006).

Activity-based probe analysis of CES1 activity in human livers
Fluorophosphonate (FP)-biotin can be used to detect functional CES1 activity in liver S9 samples. Briefly, human liver S9 fractions were suspended in 50
mM Tris-HCl (pH 7.4) buffer (1 mg protein/ml) and incubated with FP-biotin (0.2
uM final concentration) for 0, 1, 3, 5, 7 min or 30 min at room temp in a total volume of 25 μl. FP-biotin is a serine hydrolase activity-based probe (Liu et al.,
1999) and was added from a DMSO stock (final DMSO concentration in reactions, 2% v/v). Activity-based probe reactions were terminated by addition of 10
μl of 6x SDS-PAGE loading buffer and were heated at 95°C (5 min). Samples
were cooled and immediately loaded on a 10% SDS-PAGE gel. Following electrophoresis, proteins were transferred to a PVDF membrane. After blocking with
3% (w/v) non-fat milk, the membrane was probed with avidin-HRP (Sigma,
1:3000 v/v) for 30-60 min at room temp. The membrane was then washed 4x
(~5-10 min each) with Tween buffer, and the Enhanced chemiluminescent substrate (Pierce) was added for 5 min. The chemiluminescent signals on the membrane were captured on x-ray film and band intensities determined by densitometry using Image J (NIH). Plots of normalized integrated band density of native
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CES1 versus reaction time were created. Control reactions consisted of proteomes that were heat denatured before treating with FP-biotin.

Arachidonic acid-mediated inhibition of recombinant human CES1
Inhibition of the carboxylesterase activity of human recombinant CES1 by
AA was measured by AA’s effect on the hydrolysis of p-nitrophenyl valerate.
Briefly, triplicate reactions were performed in 50 mM Tris HCl (pH 7.4) buffer containing arachidonic acid concentrations varying from 0 - 100 μM in a total reaction
volume of 300 μl. Pure recombinant CES1 protein (0.12 μg) was added in each
reaction. After pre-incubation of the protein and AA for 5 min at 37° C, reactions
were initiated by the addition of 150 μl of freshly prepared 1 mM p-nitrophenyl
valerate to each well. The reactions were monitored in a plate reader by measuring absorbance (A405) for 5 min.

Activity-based probe analysis of 27-HC- and 22(R)-HC-mediated inhibition
of CES1
To study the inhibition of the carboxylesterase activity of human recombinant CES1 by 27-hydroxycholesterol, we designed an activity-based proteomic
probe competitive experiment (Leung et al., 2003). Briefly, the recombinant
CES1 protein (0.1 μg) was pre-incubated with vehicle (ethanol) or increasing
concentrations of 27-HC (0.001, 0.01, 0.1, and 1.0 μM) for 30 min at room temp
in a total volume of 25 μl 50 mM Tris-HCl (pH 7.4) buffer. After 30 min, FP-biotin
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was added to each sample from a DMSO stock to yield a final concentration of
0.2 μM and allowed to incubate for 7.5 min at room temp (final DMSO concentration, 2% v/v). Activity-based probe reactions were terminated by addition of 10 μl
of 6x SDS-PAGE loading buffer and were heated at 95°C (5 min). Samples were
cooled and immediately loaded on a 10% SDS-PAGE gel. Following electrophoresis, proteins were transferred to a PVDF membrane and biotin-labeled CES1
protein detected with avidin-HRP as described above. Plots of integrated band
density of labeled recombinant CES1 versus 27-HC concentrations were created
and the IC50 value for 27-HC was determined.

Quantitation of arachidonic acid in human livers
Non-esterified arachidonic acid levels in the human liver samples were
determined in the following manner. Approximately 0.025-0.05 g of human liver
was weighed into a glass scintillation vial. One-mL of aqueous 1% (w/v) NaCl
was added to the weighed human liver samples followed by 2 mL of CHCl3 and 1
mL of MeOH. The livers were homogenized using a Branson sonicator probe on
ice in a biosafety hood. After homogenization, 10 μl of 2.6 mM AA-d8 (deuterated
arachidonic acid internal standard) was added to the homogenate. The homogenates were centrifuged (3,500 rpm, 10 min) and the organic layer transferred to a
clean test tube (16x100 mm). The homogenates were re-extracted with 2:1:2
(v/v/v) CHCl3: MeOH: 1% NaCl/1% formic acid solution. The mixture was centrifuged again and the organic layers were combined and evaporated to dryness
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under nitrogen gas. The residues were suspended in 1:1 (v/v) methanol/isopropanol (200 μL), filtered (0.22 μm), and the clear filtrate transferred to
LC vials containing a volume reducing insert for targeted LC-MS analysis of arachidonic acid. The endocannabinoids, 2-AG and AEA, could also be analyzed in
the same LC-MS run.

Western blot analysis of CES1, FAAH, and MAGL in THP-1 cell lysate
THP-1 monocyte lysate protein was subjected to SDS-PAGE. Following
electrophoretic transfer, PVDF membranes were probed with rabbit anti-CES1
(1:4000), rabbit anti-FAAH (1:250), or rabbit anti-MAGL (1:133) for 1h at room
temperature. The membranes were then washed followed by incubation with
goat anti-rabbit secondary antibody conjugated to HRP (1:20,000). The chemiluminescent signal was recorded using X-OMAT photographic film (Eastman Kodak Co., Rochester, NY).

2-AG and PG-Gs hydrolysis by recombinant CES1 and CES2 protein
2-AG and PG-Gs contain ester bonds, so they might be hydrolyzed by
carboxylesterase. Briefly, duplicate or triplicate reactions were performed in
0.01% fatty -acid free bovine serum albumin (BSA) in 50 mM Tris HCl (pH 7.4)
buffer containing substrate concentrations varying from 0 - 250 μM (for PG-Gs)
and 0 – 400 μM (for 2-AG) in a total reaction volume of 50 μl. After pre-incubation
of buffer and substrate for 5 min at 37° C, reactions were initiated by the addition
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of 0.2 μg of pure CES1 or CES2 enzyme. The reactions were quenched after a
10 min incubation with an equal volume of acetonitrile containing 2.79 μM of internal standard 8-iso prostaglandin F2α -d4 (for PG-Gs) or 10 μM of internal standard arachidonic acid -d8 (for 2-AG). Reactions were subsequently placed on ice
for ~15 min. Samples were centrifuged at 16,000 x g (4° C) for 5 min to remove
precipitated protein prior to transferring supernatants into HPLC vials. Supernatants were analyzed for the hydrolysis products prostaglandin E2, prostaglandin F2α, or arachidonic acid by LC-MS methods described previously (Streit
et al., 2008).

Kinetic analysis of CE-mediated hydrolysis of 2-AG and PG-Gs
The enzymatic activity versus substrate concentration data was fit by nonlinear regression analysis to the Michaelis-Menten equation using Sigma Plot v.
8.02. The kinetic parameters Vmax (maximum velocity), kcat (enzyme turnover
number), Km (Michaelis constant), and kcat/Km (catalytic efficiency) were obtained.

Inhibition of CES1 and MAGL in THP-1 monocyte lysates using smallmolecule inhibitors
To determine the ability of three small-molecule inhibitors, S-3030, NAM,
and JZL184, to inhibit hydrolysis activity in THP-1 monocyte lysates, we used
PGE2-G (for S-3030, NAM, and JZL184), PGF2α-G (for JZL184), and 2-AG (for
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JZL184) as substrates. For S-3030 and NAM, triplicate reactions contained 60 μg
of THP-1 monocyte lysate and S-3030 or NAM (from 0 - 100 μM) in a total reaction volume of 50 μl of 50 mM Tris-HCl (pH 7.4) buffer. After pre-incubation of
THP-1 lysate and inhibitors for 30 min at 37° C, reactions were initiated by the
addition of 25 μM of PGE2-G. The reactions were quenched after 30 min with an
equal volume of acetonitrile containing 2.79 μM of internal standard 8-iso prostaglandin F2α -d4. The reactions were subsequently placed on ice. For JZL184,
triplicate reactions contained 27 μg of THP-1 monocyte lysate and S-3030 or
NAM (from 0 – 0.5 μM) in a total reaction volume of 50 μl of 50 mM Tris-HCl (pH
7.4) buffer. After pre-incubation of THP-1 lysate and inhibitors for 30 min at 37° C,
reactions were initiated by the addition of 25 μM of PG-Gs or 10 μM of 2-AG. The
reactions were quenched after a 30 min incubation with an equal volume of acetonitrile containing 2.79 μM of internal standard 8-iso prostaglandin F2α -d4 or 10
μM of internal standard arachidonic acid -d8. The reactions were subsequently
placed on ice. Quenched reactions were centrifuged at 16,000 x g (4° C) for 5
min to remove precipitated protein prior to transferring supernatants into LC vials.
The supernatants were analyzed by LC-MS for the hydrolysis products: prostaglandin E2, prostaglandin F2α, or arachidonic acid (Streit et al., 2008).

Immunoprecipitation of CES1 protein from THP-1 monocyte lysates
THP-1 monocyte lysates were incubated overnight with preimmune IgG
(used as control) or anti-CES1 IgG in the presence of protein A-agarose beads to
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isolate CES1 protein and deplete it from THP-1 monocyte lysates, as described
in detail in Crow et al. (2008).

PG-G hydrolysis by immunodepleted THP-1 monocyte lysates
CES1 protein was immunodepleted from THP-1 monocyte lysates. We
used PG-Gs as a substrate to be hydrolyzed by the immunodepleted THP-1 cell
lysate. Briefly, triplicate reactions were performed in 50 mM Tris HCl (pH 7.4)
buffer containing 25 μM PG-Gs in a total reaction volume of 50 μl. After preincubation of buffer and substrate for 5 min at 37° C, reactions were initiated by
the addition of 10 μg of control or immunodepleted THP-1 cell lysate. The reactions were quenched after a 30 min incubation with an equal volume of acetonitrile containing 2.79 μM of internal standard 8-iso prostaglandin F2α -d4. The reactions were subsequently placed on ice. Samples were centrifuged at 16,000 x g
(4° C) for 5 min to remove precipitated protein prior to transferring supernatants
into HPLC vials. The supernatants were analyzed for the hydrolysis product prostaglandin E2 or prostaglandin F2α by LC-MS (Streit et al., 2008).

2-AG hydrolysis by recombinant human CES1 and MAGL proteins following treatment with OP oxons
To compare the relative inhibition potency of OP oxons for CES1 and
MAGL, the following experiments were designed. Reactions were performed in
50 mM Tris-HCl (pH 7.4) buffer containing OP oxons concentrations varying re22

spectively from 0 – 100,000 nM in a total volume of 50 μl. Pure CES1 or MAGL
enzymes (0.5 μg) were added to each reaction. After pre-incubation of enzyme
and oxon inhibitor for 15 min at 37° C, reactions were initiated by the addition of
25 μM of 2-AG in each reaction. The reactions were quenched after 15 min with
an equal volume of acetonitrile containing 2.5 μM of internal standard arachidonic
acid–d8. The quenched reactions were subsequently placed on ice. Samples
were centrifuged at 16,000 x g (4° C) for 5 min to remove precipitated protein
prior to transferring supernatants into LC vials. The supernatants were analyzed
for the hydrolysis product arachidonic acid by LC-MS (Streit et al., 2008).

2-AG and PG-Gs hydrolysis by intact THP-1 monocytes following OP treatments
We hypothesized that exposure of human THP-1 cells to OP oxons would
inhibit ability of CES1 to degrade prostaglandin glyceryl esters and 2arachidonoyl glycerol. Test this, cultured THP-1 monocytes (1 x 106 cells/ml, 1.0
mL total volume) were placed in six 1.5-mL microfuge tubes in PBS. Paraoxon
from an ethanol stock solution was diluted 1:10 in a separate aliquot of fresh culture medium and added to the cells to give the desired final concentration (1.0
μM). The final concentration of ethanol in the medium in all tubes was always 1%
(v/v). The monocytes were exposed to the paraoxon for 1 hour. Following
paraoxon exposure, 2-arachidonoyl glycerol, prostaglandin E2-1-glyceryl ester or
prostaglandin F2α-1-glyceryl ester from the ethanol stock solution was diluted
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1:10 in a separate aliquot of medium and added to the medium containing the
cells to give the desired final concentration (10 μM or 25 μM). The cells were incubated with the lipid mediators for additional 1 hour. After 1 h incubation period
was complete, reactions were quenched with an equal volume of acetonitrile
(containing 2.79 μM of internal standard 8-iso-prostaglandin F2α -d4 or 10 μM arachidonic acid-d8) and 3 mL of ethyl acetate containing 0.1% acetic acid. The
samples were vortexed for 1 min and then centrifuged at 2,500 x g for 5 min. The
organic layer (top layer) was collected in glass tubes and evaporated to dryness
under N2. Residues were resuspended in 200 μl of ACN: H2O (v/v, 1:1) and
passed through microfuge filters to clarify the samples. The samples were analyzed for the hydrolysis product prostaglandin E2, prostaglandin F2α, or arachidonic acid by LC-MS (Streit et al., 2008).

S-3030

N-arachidonoyl maleimide
(NAM)

JZL 184

Scheme 5. Small-molecule inhibitors: S-3030, NAM, and JZL184
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CHAPTER IV
RESULTS AND DISCUSSION

Interindividual variation in human liver CES1 activity
It was previously reported by our laboratory that CES1 protein levels are
approximately 60-fold higher than CES2 protein amounts in pooled human liver
microsomes (Godin et al., 2007). Furthermore, it was observed that individual
human liver microsomes have varying levels of hydrolysis activities when probed
with either model ester substrates or ester-containing toxicants (Ross et al.,
2006). Therefore, interindividual variation in CES1 protein levels and enzyme activities in 25 individual human (healthy) liver samples was examined in this study.
Western blotting was used to measure CES1 protein abundance in S9 liver fractions (contains the cytosolic and microsomal fractions) and enzyme activity was
measured by using a pyrethroid insecticide substrate (bioresmethrin), which is
hydrolyzed specifically by CES1 (Ross et al., 2006).

Measurement of CES1 protein and biochemical activity in human liver
Increasing amounts of protein from a representative human liver S9 sample were loaded onto an SDS-PAGE gel to determine the appropriate amount for
quantitative western blotting (Figure 1). It was determined that 0.2 μg
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of liver S9 protein from each individual human liver was the proper amount to
load on SDS-PAGE gels because it was within the linear region of the CES1
band intensity vs. S9 protein amount curve (Fig. 1).
Since multiple gels needed to be run on different days, an internal protein
standard (His-tagged β-actin, 1 μg) was added to each individual liver sample to
control for sample loading and gel-to-gel variation. His-tagged proteins are not
produced naturally and can be recognized by specific antibodies that react with
the His tag. The relative quantities of CES1 protein were determined by using the
ration of the intensity of the CES1 band to the His-tagged β-actin band for each
liver sample. Western blots indicated that the 25 individual human liver samples
express nearly equal amounts of CES1 protein (Fig 2A). This is based on the fact
that the intensity of the protein bands is similar in all liver samples (coefficient of
variation, 9%). However, the livers have varying amounts of CES1 biochemical
activity (Fig. 2B), based on their ability to hydrolyze a CES1-specific substrate,
bioresmethrin (coefficient of variation, 50%). The mere abundance of CES1 protein expression in human liver does not appear to predict its biochemical activity.
This result was confirmed in two ways using the activity based probe, FPbiotin, which reacts covalently with enzymatically active serine hydrolases but not
with inactive or denatured proteins (Fig. 3). First, a poor metabolizer (HL1202)
and good metabolizer (HL1274) of bioresmethrin were treated with 0.2 μM FPbiotin for increasing time (0-7 min). The intensity of the CES1 band in HL 1202 is
faint and similar from 1 to 7 min, while the intensity of the CES1 band in HL1274
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is strong and steadily increased from 1 to 7 min (Fig. 4). Second, eight liver samples, including four good metabolizers and four poor metabolizers, were treated
with 2 μM FP-biotin and the extent of CES1 labeling determined (Fig. 5). Both
heat denatured and native (non-denatured) samples of each individual were
treated with the probe. FP-biotin distinguished the functional activity of CES1 in
each liver sample. Poor and good metabolizers had faint and strong CES1 bands,
respectively. The results shown in Figs. 4 and 5 are consistent with results
shown in Fig. 2B and demonstrate that variable CES1 biochemical activities exist
in a human population.

Newly identified inhibitors for CES1
While much has been learned about the metabolism of ester-containing
xenobiotics by CEs, including how some xenobiotics can inhibit this enzyme, little
is known about endogenous inhibitors and substrates that may interact with
these proteins and affect their activity.

Inhibition of human CES1 by the endogenous compounds, arachidonic acid and
27-hydroxycholesterol
The levels of CES1 protein in each individual human liver sample are
remarkably similar, while their biochemical activities are very different. One
possibility to explain these results is the presence of endogenous inhibitors in
human liver that might inhibit CES1 activity. Arachidonic acid (AA) and 2727

hydroxycholesterol (27-HC) are two endogenous compounds identified by our
laboratory as potent inhibitors of recombinant human CES1 activity (Crow et al.,
2009) (Fig. 6 and Fig. 7). Ki values for AA and 27-HC are 1.7 μM and 10 nM, respectively (Crow et al., 2009), indicating that 27-HC is a more potent inhibitor
than arachidonic acid. Interestingly, it was found that isomeric oxysterol 22(R)HC does not inhibit CES1 (Fig. 7). Furthermore, both AA and 27-HC inhibit
CES1, but not CES2, thus CE isoform selectivity is seen for these inhibitors.

Quantitation of arachidonic acid in human liver
Based on the above findings, we hypothesized that levels of AA and 27HC in individual human livers may be inversely correlated with CES1 biochemical
activity. We measured the amount of free (unesterified) AA in human liver extracts by LC-MS analysis. However, we did not find evidence that the amount of
AA present in human livers is inversely correlated with CES1 biochemical activity
(Fig. 8, r2 = 0.0061, p>0.05). Extraction of four S9 fractions (two poor metabolizers and two good metabolizers) instead of whole liver and quantitation of AA by
LC-MS also did not indicate that high quantities of AA were present in the poor
metabolizers livers and low quantities in the good metabolizers livers (data not
shown).
When CES1 specific activities in the 25 human liver samples were divided
into tertiles (low tertile, <1000 pmol/min/mg; mid tertile, >1000 pmol/min/mg and
<2000 pmol/min/mg; high tertile, >2000 pmol/min/mg) and the lipid composition
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(AA and the endocannabinoids, 2-arachidonoyl glycerol and anandamide, which
were measured in the same LC-MS analysis) of the three groups were compared,
no trends were observed that would suggest that the differential enzymatic activities of the liver samples were related to the liver content of these particular lipids
(Fig. 9).
This study has taken a first step in the direction of defining the relationship
between the amount of AA and the biochemical activity of CES1 in 25 human
liver samples. We focused on AA because it is more abundant than 27-HC in
liver and methods that permit analysis of AA using a single-quadrupole mass
spectrometer were available to us. The findings, however, go against our hypothesis. Our results demonstrate that AA levels and CES1 biochemical activity
in 25 human liver samples are not correlated. A future study might try to quantify
hepatic levels of 27-HC because it is a more potent inhibitor of CES1 activity than
AA (Crow et al., 2009). In addition, other possibilities to account for interindividual variation in CES1 activity can be postulated, including variations in amino
acid sequence (polymorphisms), post-translational modifications (PTMs) in CES1
proteins, protein-protein interactions that can alter the hydrolytic activity of the
enzyme or the availability of AA. These should be investigated in the future.

Newly identified substrates for CES1 and CES2
We hypothesized that the natural cannabinoid receptor ligand, 2arachidonoyl glycerol (2-AG), and its COX-2-derived metabolites, prostaglandin
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glyceryl esters (PG-Gs), are substrates for human CEs because each of these
compounds contains ester bonds.

Hydrolysis of the endocannabinoid, 2-AG, by human recombinant CES1 and
CES2
2-AG can be hydrolyzed by recombinant human CES1 and human CES2
into AA and glycerol (Fig. 10A). LC-MS analysis can measure the velocity of this
reaction by measuring the amount of product (AA) formed in a specified amount
of time (Fig. 10B). The substrate concentration-velocity data in Fig.10C were fit to
the Michaelis-Menten equation [v = Vmax × [S]/(Km + [S])] using Sigma Plot and
the kinetic parameters were obtained (shown in Table 1). The rate of turnover of
2-AG (kcat = Vmax/[E]0) by CES1 is higher than CES2; but there is no remarkable
difference between the catalytic efficiency (kcat/Km) parameters for CES1 and
CES2 (Table 1).
In contrast to 2-AG, the other endocannabinoid, 2-arachidonoyl ethanolamine (AEA), which contains an amide bond instead of an ester bond, is not hydrolyzed by either CES1 or CES2 (Table 2).

Hydrolysis of PG-Gs by human recombinant CES1 and CES2
PGF2α-G and PGE2-G are also hydrolyzed by human CES1 and CES2 into
free prostaglandins, PGE2 and PGF2α (Fig. 11). Kinetic parameters were determined
by fitting data to Michaelis-Menten equation (shown in Table 3). Based on catalytic
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efficiencies (kcat/Km), PGF2α-G is a better a substrate for both human CES1 and
CES2 than PGE2-G (Table 2). After inspecting published kcat/Km values for
recombinant rat MAGL (Vila et al., 2007), it appeared that human CES1 and CES2
were better catalysts of PG-G hydrolysis than the rat MAGL. For example, kcat/Km
values for PGF2α-G and rat MAGL are 30-89-fold lower than what we observe for
CES1 and CES2, while kcat/Km values for PGE2-G and rat MAGL are 3-5-fold lower
than for CES1 and CES2. We attempted to confirm this finding using recombinant
human MAGL enzyme; however, the data revealed a significant species difference
between rat and human MAGL activity. When recombinant human MAGL was used
to hydrolyze PGE2-G and PGF2α-G, we estimated kcat/Km values to be 1.6 and 0.31
min-1 μM-1, respectively. This data suggests that human MAGL and human CES 1
and 2 have generally similar abilities to hydrolyze PGE2-G and PGF2α-G. But that
human MAGL is much more efficient than rat MAGL in hydrolying these esters.
CES1 can hydrolyze 2-AG and PG-Gs because both compounds have ester
bonds. PGE2-G and PGF2α-G have very similar structure, but PGF2α-G is more efficiently metabolized than PGE2-G by both CES1 and CES2 recombinant proteins.
Compared to CES1, which has a substrate specificity factor of 2 for PGF2α-G over
PGE2-G, the substrate specificity factor for CES2 is 13 for PGF2α-G over PGE2-G.
One possible explanation for this substrate preference for PGF2α-G by human CEs is
that the PG-Gs used have two different functional groups that distinguish them:
PGF2α-G has a β-hydroxyl functional group on the C9 position of the cyclopropane
ring, while PGE2-G has a carbonyl functional group instead at the same position.
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The hydroxyl group might cause PGF2α-G to have a higher affinity for CES1 and
CES2 proteins, perhaps because of a critical hydrogen bond being formed in the active site.

Expression of endocannabinoid hydrolyzing enzymes in THP-1 monocytes
In order to determine if THP-1 monocytes can express fatty acid amide
hydrolase (FAAH), monoacylglycerol lipase (MAGL) or human carboxylesterase
1 (CES1), we used western blotting to detect them. This was done because
FAAH and MAGL are known to hydrolyze endocannabinoids (Vila et al., 2007).
From the western blots of THP-1 cell lysates, we can conclude that THP-1 cells
express both MAGL and CES1, but not FAAH (Fig. 12). It also should be noted
here that CES2 is not expressed in cultured human THP-1 monocytes (Crow et
al., 2008). We focus our attention on the human immune cell line, THP-1 monocytes/macrophages, because these cells are a good model for inflammatory
mechanisms study. Since several diseases such as atherosclerosis and diabetes
have inflammatory components, these cells are useful for the study of disease
initiation and progression.

Comparison of the ability of endocannabinoid hydrolyzing enzymes to metabolize
2-AG and PGE2-G
As mentioned, MAGL and FAAH have been previously reported to hydrolyze 2-AG and PGE2-G (Vila et al., 2007), but CES1 has not. Therefore, these
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three enzymes were directly compared using a single concentration of each substrate (Fig. 13). For 2-AG, the three enzymes hydrolyze the endocannabinoid at
similar rates. For PGE2-G, rank order of hydrolysis rates was as follows:
MAGL>CES1>>FAAH. The enzymatic activity of CES1 would appear to be similar or greater than the previously reported MAGL and FAAH.

Inhibition of CES1 and MAGL using small molecules, S-3030 and NAM
Since MAGL and CES1 are both expressed in THP-1 monocytes, small
molecule inhibitors of each enzyme were used to determine their relative contribution to the metabolism of 2-AG and PG-Gs.
A cross-inhibition study was performed in which we used 50 μM NAM
(MAGL inhibitor) and 50 μM S-3030 (CES1 inhibitor) to pre-treat recombinant
human CES1 and MAGL enzymes, respectively. The extent of 2-AG hydrolysis
by the enzymes was then determined (Fig. 14). It was found that CES1 is an offtarget for NAM (50-60% inhibition of pure enzyme at 50 μM NAM; Fig 14A), while
MAGL is not an off-target for S-3030 (Fig. 14B). Thus NAM cannot be called a
selective inhibitor of MAGL. We also discovered that JZL 184, another reported
selective inhibitor of MAGL, can inhibit CES1 (data not shown).
THP-1 monocyte lysates were then pretreated with increasing concentrations of S-3030 (CES1 inhibitor) followed by addition of synthetic 2-AG (25 μM)
(Fig. 15). 2-AG hydrolysis activity in the lysate was reduced by S-3030 in a concentration dependent manner (maximum reduction ~60% at 100 μM S-3030), in33

dicating that CES1 does have a role in metabolizing 2-AG in THP-1 cells. However, complete inhibition was not observed, so another enzyme(s) is likely to also
have a role. It is currently not clear what this enzyme is; however, MAGL may be
ruled out based on data described below.
We then studied the metabolism of PG-Gs by THP-1 monocytes in the absence or presence of selective inhibitors. First, it was shown that intact cultured
THP-1 monocytes could metabolize PGE2-G and PGF2α-G when these compounds were added to the culture medium (Fig. 16). PGE2-G was hydrolyzed to
free prostaglandin to a greater extent than PGF2α-G, which is surprising since
PGF2α-G is hydrolyzed more efficiently by CES1 than PGE2-G. One possible
reason is that PGF2α-G may be metabolized by alcohol dehydrogenases more
efficiently than PGE2-G in THP-1 cells, thus reducing the PGF2α-G concentration
available to be hydrolyzed by CES1.
Second, THP-1 monocyte lysates were pretreated with increasing concentrations of S-3030 or NAM followed by addition of synthetic PGE2-G (25 μM). The
data shows that selective inhibition of CES1 by S-3030 significantly reduces the
rate of PGE2-G hydrolysis catalyzed by THP-1 cell lysate (Fig. 17A); PGE2-G hydrolysis activity is nearly completely blocked by 100 μM S-3030. Adding the
MAGL inhibitor, NAM, to THP-1 cell lysate also reduces PGE2-G hydrolysis rates,
but not to the degree that S-3030 does (Fig. 17B). Because CES1 is an off-target
of NAM, it is possible that inhibition seen in Fig. 17B is due to blockage of CES1
activity by NAM.
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Hydrolysis of 2-AG and PG-Gs by THP-1 monocyte lysates and intact cells and
inhibition of this activity by bioactive metabolites of OP insecticides

Inhibition of recombinant CES1 and MAGL
In this study, we wished to determine the relative sensitivities of recombinant human CES1 and MAGL toward two bioactive insecticide metabolites,
paraoxon (PO) and chlorpyrifos oxon (CPO). The recombinant enzymes were
pretreated with increasing amounts of PO and CPO for 15 min followed by addition of 2-AG substrate (10 μM). The results show that PO preferentially inhibits
CES1 over MAGL, while CPO can inhibit both enzymes (although CES1 appears
more sensitive than MAGL) (Fig. 18). Interestingly, even at high concentrations of
paraoxon very little inhibition of MAGL results (Fig. 18). According to these results, it is concluded that MAGL is insensitive to PO, but CES1 is not; and both
MAGL and CES1 are sensitive to CPO-mediated inhibition.

Hydrolysis of 2-AG and PG-Gs by intact THP-1 monocytes following PO
pretreatment
Because PO can inhibit CES1 but not MAGL, this oxon is then an excellent probe to distinguish MAGL and CES1 activities in THP-1 cells. Following
pre-treatment of intact THP-1 monocytes with PO (1μM, 30 min), the ability of the
cells to hydrolyze exogenous 2AG, PGE2-G, and PGF2α-G (25μM, 1 h) was significantly inhibited (Fig. 19). The remaining hydrolytic activity in the 1 μM PO
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group may be attributed to uninhibited (and uncharacterized) enzymes that can
hydrolyze these lipid mediators or to incomplete inhibition of native CES1 in the
THP-1 monocytes.

Hydrolysis of 2-AG by THP-1 monocytes lysate following PO or CPO pretreatments
We hypothesized that since MAGL and CES1 are both inhibited by 1000
nM CPO (Fig. 18), but only CES1 by 1000 nM PO, that differential inhibition of 2AG hydrolysis activity would be observed when THP-1 cell lysate proteins were
treated with these oxons. Following pretreatment of THP-1 monocyte lysates
with PO or CPO (1μM, 30 min), the ability of the cells to hydrolyze exogenous 2AG (10μM, 1 h) was significantly inhibited (~50-55%, Fig. 20). However, essentially no difference in inhibition potency was observed for PO and CPO. Thus,
the remaining 2-AG hydrolytic activity that is not inhibited by either PO or CPO
may be attributed to OP-insensitive enzyme(s). It was previously reported that
such an OP-insensitive lipase activity exists in THP-1 monocytes when the
fluorogenic substrate 4-methylumbelliferyl oleate was used as the enzyme probe
(Crow et al., 2008). The identity of this enzyme remains unknown.
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Hydrolysis of PGE2-G by intact THP-1 monocytes or macrophages following PO pretreatment
Pretreatment of intact monocytes or macrophages with increasing concentrations of PO prior to addition of synthetic PGE2-G caused concentrationdependent inhibition of PGE2-G hydrolysis activity in both cell types (Fig. 21).
Pronounced inhibition was seen at PO concentrations as low as 100 nM, which
indicates that CES1 (but not MAGL) has a role in this metabolism.

Immunodepletion of CES1 protein from THP-1 cell lysate
In this study, THP-1 monocyte lysate was incubated overnight with preimmune IgG (used as control) or anti-CES1 IgG antibodies to immunoprecipitate
CES1 protein and deplete the protein from THP-1 monocyte lysate. The western
blots of preimmune IgG- and anti-CES1 IgG-treated samples showed that CES1
protein was successfully depleted from the THP-1 cell lysate treated with antiCES1 antibody (Fig. 22A).
The CES1-immunodepleted lysates were then incubated with 25 μM of
each PG-G substrate and hydrolysis product assayed by LC-MS analysis (Fig. 22
B,C). From this data, it appears that CES1 accounts for a major fraction of the
PG-G hydrolysis activity in THP1 cell lysates. It also suggests that PGE2-G is
nearly quantitatively metabolized by CES1 in THP-1 cells. The remaining activity
in the immunodepleted cell lysates, particularly in the case of PGF2α-G, is possibly due to presence of other enzymes that can metabolize PG-Gs.
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Figure 1. Western blot of CES1 protein in titrated human liver S9 fraction.
Increasing amounts (0.1-2.0 μg) of denatured human liver S9 protein
were loaded in each well of an SDS-PAGE gel. The intensity of the immunoreactive bands was measured and a CES1 band intensity vs. protein amount plot was
made. The dashed line indicates the linear regression curve (equation and correlation coefficient are shown). According to the curve, 0.2 μg of S9 protein was
within the linear region.
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Bioresmethrin hydrolysis activity
(pmol/min/mg protein)
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O
O
bioresmethrin

O

Figure 2. The mere abundance of CES1 protein expression in human liver does
not predict its biochemical activity.
(A) Human liver S9 proteins were subjected to SDS-PAGE analysis and
immunoblotting using anti-CES1 and anti-His antibodies. A similar quantity of
His-tagged β-actin (1 μg) was added to each sample before electrophoresis for
use as internal standard and to control inter-gel variations. (B) Human liver S9
samples were used to determine their hydrolytic activity against a CES1-specific
substrate, bioresmethrin. This substrate is not hydrolyzed by CES2, only CES1.
Bioresmethrin hydrolysis reactions using human S9 fractions were performed in
50 mM Tris-HCl buffer (pH 7.4) after adding 2.5 μL of 5 mM fresh bioresmethrin.
Reactions were terminated after 15 min with 250 μL acetonitrile containing an internal standard (10 μM 3-(4-methoxy)-phenoxybenzaldehyde). After centrifugation, the supernatant was analyzed by HPLC/UV. All reactions were performed in
triplicate and specific activities are reported as pmol/min/mg protein (CV<15% for
each sample). The specific activity of each individual liver sample is plotted in
the order from poorest metabolizer to greatest metabolizer of bioresmethrin.
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Biotinylated proteins, following
transfer to PVDF membrane, are
recognized by avidin-horse radish
peroxidase (HRP) conjugates

biotin tag

Figure 3. Inhibition of serine hydrolase family of enzymes by reversible or irreversible inhibitors can be evaluated using the activity-based probe,
fluorophosphonate (FP)-biotin.
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Figure 4. Time-course of reaction between FP-biotin and two human liver samples (HL1202 and HL1274).
(A) HL1202 and HL1274 are poor and good metabolizers of bioresmethrin,
respectively (same data as presented in Fig. 2B). (B) Avidin-HRP blotting of
biotinylated proteins following a 0–7 min reaction of the two liver samples with
0.2 μM FP-biotin. The CES1 protein is indicated with an arrow. The arrow designated as “Non specific” refers to proteins that are not enzymatically active, but
are still labeled by FP-biotin.
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Figure 5. Fluorophosphonate (FP)-biotin can distinquish the functional activity of
CES1 in complex proteomes. The intensity of the hCE1 (CES1) band
in each human liver S9 sample is related to its intrinsic biochemical
activity.
Liver proteins (1 mg/ml) were treated with 2-µM FP-biotin for 1 h at room
temperature. The quenched reactions were subjected to SDS-PAGE, transferred
to PVDF membranes and probed with avidin conjugated to HRP to detect FPbiotin-labeled proteins. Note the difference between sample 1202 (a poor metabolizer) and 1274 (a good metabolizer). The + pre-heat labeled bands correspond to proteins that react with FP-biotin after heat denaturation of liver proteins,
which result from non-specific binding of FP-biotin to protein. “Non specific” refers to proteins that are not enzymatically active, but are still labeled by FP-biotin
in the absence or presence of heat denaturation.
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Figure 6. Inhibition of the carboxylesterase activity of human recombinant CES1
by AA. Hydrolysis of p-nitrophenyl valerate by CES1 in the presence
of arachidonic acid was measured by a spectrophotometric assay.
The data were fit to an equation that describes noncompetitive enzyme
inhibition (Webb, 1963): i = [I]/([I] + Ki). The combined data from 3-4 independent experiments are shown (error bars, SD, represent the intra-assay variation
for each independent experiment).
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Figure 7. Activity blots of recombinant CES1 following pretreatment with 27-HC
or 22(R)-HC. 27-HC is a potent inhibitor of CES1 (Left), but 22(R)-HC
is not (Right).
Inhibition of the carboxylesterase activity of human recombinant CES1 by
27-hydroxycholesterol, but not 22(R)-hydroxycholesterol: Reaction of CES1 with
0.2 μM FP-biotin after pretreatment with increasing concentrations of 27-HC and
22(R)-HC.
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AA amount vs. CEs activity of human liver samples
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Figure 8. The levels of arachidonic acid (AA) vs. CES1 activity in human liver
samples.
AA was extracted from human liver samples and then analyzed by LC-MS
and an AA vs. bioresmethrin activity (CES1 activity) curve was made. According
to the curve, the amount of arachidonic acid present in human livers were not
correlated with CES1 activity (r2 = 0.0061, p>0.05).
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Figure 9. Content of arachidonic acid and endocannabinoids in human livers
(A) The CES1 specific activities (determined using the pyrethroid insecticide, bioresmethrin) of the liver samples were divided into three groups (tertiles).
Significant differences in enzymatic activities were noted when the mid and high
tertile groups were compared to the low tertile group (* p<0.05, one-way ANOVA
and Dunnett’s test). (B) The quantities of arachidonic acid and endocannabinoids
(anandamide and 2-arachidonoyl glycerol) in the liver samples did not parallel the
CES1 hydrolytic activity in the three tertile groups.
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Figure 10. 2-arachidonoyl glycerol hydrolysis by recombinant human CES1 and
CES2.
(A) Chemical scheme of the 2-AG hydrolysis reaction catalyzed by human
CEs. (B) The amount of arachidonic acid (AA) product formed between 10 and
75 min incubation of 2-AG with CES1 was determined by LC-MS analysis (m/z
302, negative ion mode). (C) Substrate concentration vs. velocity (rate of turnover of 2-AG) curves for human recombinant CES1 and CES2. Recombinant
human CES1 and CES2 (0.2 μg/reaction) were incubated with 2-arachidonoyl
glycerol for 20 min at 37°C in 50 mM Tris-HCl (pH 7.4) containing 0.01% w/v
fatty-acid free BSA. Kinetic parameters for each enzyme, determined by fitting
the data to the Michaelis-Menten equation, are presented in Table 1 below.
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Figure 11. Substrate concentration vs. velocity (rate of turnover of PGE2-G or
PGF2α-G) curves for recombinant human CES1 and CES2.
Recombinant human CES1 (left panel) and CES2 (right panel) (0.2
μg/reaction) were incubated with the prostaglandin glyceryl esters, PGF2α-G or
PGE2-G, for 10 min at 37°C in 50 mM Tris-HCl (pH 7.4) containing 0.01% w/v
fatty-acid free BSA. Kinetic parameters for each enzyme, determined by fitting
the data to the Michaelis-Menten equation, are presented in Table 3 below.
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Table 1. Steady-state Michaelis–Menten kinetic parameters for 2-arachidonoyl
glycerol hydrolysis by human recombinant CES1 and CES2.
Steady-state Kinetic Parameters
Carboxylesterase
Km (µM)
kcat/Km (min-1 µM-1)
kcat (min-1)
isozyme
CES1
59 + 4
49 + 11
1.2
CES2

43 + 4

46 + 13

0.9

Table 2. Summary of enzymes that can hydrolyze the endocannabinoids, 2arachidonoyl glycerol (2AG) and anandamide (AEA).
Substrate
O

OH

O
OH

2-Arachidonoyl glycerol
(2-AG)

O
NH

Anandamide
(AEA)

FAAH

CES1

CES2

2-AG

+

+

+

+

AEA

−

+

−

−

+, activity detected; −, no activity detected

Subst rate

OH

MAG Lipase

In vitro catalytic efficiencies (μM-1 min-1)
MAG Lipase

FAAH

CES1

CES2

2-AG

2.1

18.6

1.2

0.9

AEA

−

27.6

−

−

Data for MAG Lipase and FAAH are from Vila et al. (2007) Biochemistry 46: 9578-9585.

Abbreviations:
MAG, monoacylglycerol
FAAH, fatty-acid amide hydrolase
hCE1, human carboxylesterase 1
hCE2, human carboxylesterase 2
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Table 3. Steady-state Michaelis–Menten kinetic kinetic parameters for PG-G
hydrolysis by human recombinant CES1 and CES2.
Human CES1
-1

Substrate

kcat (min )

Km (µM)

kcat/Km (min-1 µM-1)

PGF2α-G

34.2

42.7

0.80

PGE2-G

57.9

171.7

0.34

Human CES2
Substrate

kcat (min-1)

Km (µM)

kcat/Km (min-1 µM-1)

PGF2α-G
PGE2-G

54.7
92.6

22.4
520

2.4
0.18
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Figure 12. THP-1 monocytes express CES1 and MAGL, but do not express
FAAH.
In this western blot analysis, PVDF membranes were probed for CES1,
MAGL, and FAAH proteins using rabbit anti-CES1 [1:4000 (v:v)], rabbit antiMAGL [1:133 (v:v)], or rabbit anti-FAAH [1:250 (v:v)]. Antigen-antibody complexes were detected using goat anti-rabbit secondary antibody conjugated to
HRP [1:20,000 (v:v)].
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Figure 13. Comparison of FAAH, CES1, and MAGL hydrolytic enzymes and their
ability to metabolize PGE2-G (25 μM) or 2-AG (10 μM).
Recombinant human enzymes (0.5 μg/reaction) were incubated with substrate for 15 min. Products are analyzed by LC-MS and quantified with internal
standard (8-iso-PGF2a-d4 or AA-d4). Data represent the mean ± SD of triplicate
reactions.
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Figure 14. N-arachidonoyl maleimide (NAM, 50 μM) cross-inhibits recombinant
human CES1 (A), but S-3030 (50 μM) does not inhibit recombinant
human MAGL (B).
The substrate used in this experiment was 2-arachidonoyl glycerol (25 μM
final concentration). The amount of arachidonic acid (AA) was determined by
LC-MS analysis and quantified with an internal standard (AA-d4). The extent of
product formation was determined 5, 10, and 15 min after the reaction started.
Data represent the mean ± SD of duplicate reactions.
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Figure 15. Selective inhibition of CES1 activity in THP1 monocyte lysates reduces 2-AG hydrolysis rate.
Inset, western blot of recombinant CES1 protein (left lane) and THP-1 cell
lysate (right lane) probed with anti-CES1 antibody. Bar graph, THP-1 cell lysate
was pre-incubated with increasing concentrations of the CES1-selective inhibitor
S-3030 before adding 2-AG (25 μM). The amount of arachidonic acid was quantified by LC-MS using the AA-d4 internal standard.
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Figure 16. Cultured THP-1 monocytes can metabolize synthetic PGE2-G and
PGF2α-G to free prostaglandins.
Data represent the mean ± SD of triplicate reactions. – cells, PG-G was
added to FBS-free culture medium only; + cells, PG-G added to FBS-free culture
medium + THP-1 monocytes.

55

A

B
120

PGE2-G hydrolysis activity
(% of control)

120

PGE2-G hydrolysis activity
(% of control)

O

100

100
80

Control

60
40
20
0

C

0

10

50

100

S-3030 (μM)

S

O
S

S-3030

80
60

O

40

N
O

20
0

0

10

50

100

NAM

NAM (μM)

Figure 17. Inhibition of CES1 and MAGL in THP-1 monocyte lysates using the
small molecules, S-3030 and NAM
Addition of CES1-selective inhibitor S-3030 to THP-1 monocyte lysates
reduces hydrolysis of PGE2-G (A), but addition of a monoacylglycerol lipase
(MAGL) inhibitor, NAM, is less effective (B). Structures of S-3030 and NAM are
shown in (C). Data represent the mean ± SD of duplicate or triplicate reactions.
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Figure 18. Inhibition of 2-AG hydrolysis catalyzed by recombinant human CES1
and MAGL following pretreatment with paraoxon and chlorpyrifos
oxon.
Paraoxon preferentially inhibits CES1 over MAGL, while chlorpyrifos oxon
can inhibit both enzymes although CES1 appears to be more sensitive than
MAGL. Even at high concentrations of paraoxon, very little inhibition of MAGL
results. Data represent the average of duplicate reactions.
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Figure 19. Paraoxon (PO) pretreatment of intact THP-1 monocytes reduces su
sequent hydrolysis of exogenously added 2-AG (A), PGE2-G (B), and
PGF2α-G (C).
Cells were exposed to PO for 1 h followed by addition of lipid mediators to
culture medium (and incubation for an additional 1 h). Data represent the mean
± SD of triplicate plates.
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Figure 20. Inhibition of the 2-AG hydrolysis activity of THP1 monocyte lysates
following treatment with PO or CPO.
THP1 cell lysate was pretreated with 1 µM PO or CPO for 30 min. Then
2-AG (10 µM) was added and the mixture incubated for an additional 30 min.
The amount of arachidonic acid (AA) formed was assayed by LC-MS. Data represent the mean ± SD of triplicate reactions.
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Figure 21. Intact THP-1 monocytes and macrophages were treated with the indicated concentrations of paraoxon.
After treatment with PO (24 h), cell lysates were prepared and incubated
with synthetic PGE2-G (10 μM) for 15 min. Extracts were prepared and analyzed
by LC-MS. Data represent the mean ± SD of duplicate or triplicate plates.
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Figure 22. Hydrolysis of PGE2-G and PGF2α-G by immunodepleted THP-1 lysates.
(A) Immunoprecipitation of CES1 from THP-1 monocyte lysates. Hydrolysis of PGE2-G (B) and PGF2α-G (C) by immunodepleted THP-1 lysates following
30-min incubation with substrate. Data represent the mean ± SD of triplicate reactions.
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CHAPTER V
CONCLUSIONS

The current study was conducted to examine interindividual variation of
CES1 biochemical activity in humans, and to also determine if human CES have
a role in degrading ester-containing lipid mediators, such as endocannabinoids
and oxygenated endocannabinoid metabolites (PG-Gs).
It can be concluded that the abundance of CES1 protein expression in
human liver does not predict its biochemical activity, which exhibits significant
variation when probed with a CES1-selective substrate (bioresmethrin) or an activity-based probe (FP-biotin). Human interindividual variation in CES1 activities
may be attributed to several mechanisms, including post-translational modifications, sequence polymorphisms, or protein-protein interaction. Because we
found that arachidonic acid could inhibit CES1 activity, we measured the quantity
of AA in the human livers. We did not observe a correlation between AA levels
and CES1 biochemical activity. Therefore, it is concluded that AA does not account for the interindividual variation in CES1 biochemical activity that we observe.
Recombinant human CES1 and CES2 enzymes were found to efficiently
hydrolyze 2-arachidonoylglycerol (2-AG) into arachidonic acid, and prostaglandin
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glycerol esters (PG-Gs; PGE2-G and PGF2α-G) into free prostaglandins, i.e.
PGE2 and PGF2α. The catalytic efficiencies of CES1 and CES2 toward 2-AG and
PG-Gs are similar to or better than values published for recombinant rat MAGL
and FAAH (Vila et al., 2007). Therefore, 2-AG and PG-Gs are novel endogenous
substrates for CES1 and CES2 and add to the growing list of compounds that
this enzyme metabolizes.
Using a small-molecule CES1-specific inhibitor (S-3030) or
immunodepletion, it was found that CES1 may be an important hydrolytic
enzyme for metabolizing 2-AG and PG-Gs in cultured human THP-1 monocytes.
Furthermore, bioactive pesticide metabolites (such as paraoxon) can inhibit this
biochemical activity of CES1 in THP-1 monocytes, resulting in reduced hydrolysis
rates of exogenously added 2-AG or PG-Gs. These findings suggest that exposure of CES1- and/or CES2-expressing cells to bioactive OP metabolites may
perturb the endocannabinoid and PG-G tone in tissues that are composed of
these cells. This may have implications for diseases that macrophages have major pathological role in, e.g., atherosclerosis. Future studies will need to address
one of the limitations of the current study, i.e. the reliance on supraphysiological
concentrations of 2-AG and PG-Gs to study its metabolism in the cultured cells.
Enhanced analytical methodology (e.g., LC-MS/MS) should help in this regard.
Finally, CES1 and MAGL are not the only enzymes in THP-1 monocyte
cells that can hydrolyze 2-AG and PG-Gs. A lipase is present in this cell line that
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is insensitive to the inhibitory effects of bioactive metabolites of chlorpyrifos and
parathion. The identity of this lipase is currently unknown.
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